Literature DB >> 32982590

Approach to radiation therapy in the Jehovah's Witness patient: An overview.

James M Jurica1,2, Jay A Messer2,3, Bin S Teh1, Brian E Butler1, Andrew M Farach1.   

Abstract

Jehovah's Witnesses are well-known in the medical community for their inability to accept blood products. Novel methods of treatment are often needed to avoid anemia and hematologic toxicity as inability to receive blood products may increase the risk of treatment related complications. We provide an overview of radiation treatment for Jehovah's Witness patients with an emphasis on bone marrow sparing strategies with intensity modulated radiation therapy (IMRT) to minimize hematologic toxicity.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anemia; BMS-IMRT; Bone marrow sparing; Hematologic toxicity; Jehovah witness; Radiation oncology

Year:  2020        PMID： 32982590      PMCID： PMC7494585          DOI： 10.1016/j.rpor.2020.08.014

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN： 1507-1367


  11 in total

1.  Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.

Authors:  Colton J Ladbury; Chad G Rusthoven; D Ross Camidge; Brian D Kavanagh; Sameer K Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-06-05       Impact factor: 7.038

2.  Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer.

Authors:  Nan Li; Sonal S Noticewala; Casey W Williamson; Hanjie Shen; Igor Sirak; Rafal Tarnawski; Umesh Mahantshetty; Carl K Hoh; Kevin L Moore; Loren K Mell
Journal:  Radiother Oncol       Date:  2017-05       Impact factor: 6.280

Review 3.  Cancer-related anemia: pathogenesis, prevalence and treatment.

Authors:  Gunnar Birgegård; Matti S Aapro; Carsten Bokemeyer; Mario Dicato; Peter Drings; Javier Hornedo; Maciej Krzakowski; Heinz Ludwig; Sergio Pecorelli; Hans Schmoll; Maurice Schneider; Dirk Schrijvers; Daniel Shasha; Simon Van Belle
Journal:  Oncology       Date:  2005       Impact factor: 2.935

4.  Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Authors:  Loren K Mell; David A Schomas; Joseph K Salama; Kiran Devisetty; Bulent Aydogan; Robert C Miller; Ashesh B Jani; Hedy L Kindler; Arno J Mundt; John C Roeske; Steven J Chmura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-08       Impact factor: 7.038

5.  Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis.

Authors:  Juergen Dunst; Thomas Kuhnt; Hans G Strauss; Ulf Krause; Tanja Pelz; Heinz Koelbl; Gabriele Haensgen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

6.  A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer.

Authors:  Naoya Murakami; Hiroyuki Okamoto; Takahiro Kasamatsu; Kazuma Kobayashi; Ken Harada; Mayuka Kitaguchi; Shuhei Sekii; Kana Takahashi; Kotaro Yoshio; Koji Inaba; Madoka Morota; Minako Sumi; Takafumi Toita; Yoshinori Ito; Jun Itami
Journal:  Anticancer Res       Date:  2014-09       Impact factor: 2.480

7.  Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.

Authors:  Loren K Mell; Hanifi Tiryaki; Kang-Hyun Ahn; Arno J Mundt; John C Roeske; Bulent Aydogan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-01       Impact factor: 7.038

8.  Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.

Authors:  Christian L Barney; Nicholas Scoville; Eric Allan; Ahmet Ayan; Dominic DiCostanzo; Karl E Haglund; John Grecula; Terence Williams; Meng Xu-Welliver; Gregory A Otterson; Jose G Bazan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-11-23       Impact factor: 7.038

9.  Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans.

Authors:  Cathy Menkarios; David Azria; Benoit Laliberté; Carmen Llacer Moscardo; Sophie Gourgou; Claire Lemanski; Jean-Bernard Dubois; Norbert Aillères; Pascal Fenoglietto
Journal:  Radiat Oncol       Date:  2007-11-15       Impact factor: 3.481

10.  Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer.

Authors:  Zhirong Bao; Dajiang Wang; Shupeng Chen; Min Chen; Dazhen Jiang; Chunxu Yang; Hui Liu; Jing Dai; Conghua Xie
Journal:  Radiat Oncol       Date:  2019-08-05       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.